The ESPATUE phase III randomized clinical trial evaluating the benefit of surgery for stage III NSCLC reports no measurable benefits in > 10-year survivors. #radonc #lcsm Cecilia Pompili MD PhD FACS onlinelibrary.wiley.com/doi/full/10.10…

🚨 New Insights into Patterns of Locoregional Recurrence in #PancreaticCancer after TNT & Their Impact on Neoadjuvant RT Volumes 🚨 pubmed.ncbi.nlm.nih.gov/39182645/ #PancSM #Radonc 🙌 Sara Beltrán Ponce, MD n=1/8

🚨CCTG HE.1🚨 Phase 3 RCT refractory HCC or liver metastasis with associated pain > 4/10 Randomized: Best Supportive care (BSC) vs. Single fraction palliative liver RT + BSC 🔥RT associated with ✅⬆️ Pain response ✅⬆️ QoL ✅ Trend to ⬆️ OS Congrats to Laura Dawson !!

1/4 Alright, so here are my thoughts on Radiation to Residual Disease after Targeted Therapies as presented at #WCLC24. Focusing on EGFR mutant #lungcancer where we all agree, I think, that osimertinib alone cannot be the answer, right⁉️🧐 The main risk here is secondary

❓LC-CRT vs. SC-RT for Rectal Cancer Organ Preservation❓ MSKCC SOC: LC-CRT TNT, during COVID shifted to SC-RT Study demonstrated: 🟢🟰cCR rates (~ 40%) 🟢🟰 OS and DFS 🧐 ⬇️Regrowth ⬆️Organ Preservation w/ LC-CRT 🔥Suggests LC-CRT preferred for NOM German AIO-18 to clarify

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦Dr Shaun Tolan⁩ Alison Tree 💙⁩ ⁦Clive Peedell⁩ Dr. Andrew Loblaw⁩ ⁦Prof Emma Hall⁩ Prof Joe O'Sullivan⁩ authors.elsevier.com/sd/article/S03…

⚡️Excited to share a new commentary by Dr. Kunal Sindhu and myself in NatureRevClinOncol on vorasidenib, the newly FDA-approved treatment for IDH-mutant low-grade gliomas. ❗️With no proven survival or quality of life benefit over standard chemoradiotherapy and serious ethical

Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial out in European Urology sciencedirect.com/science/articl… The PACE-A trial is a phase 3⃣ randomized study comparing patient-reported outcomes between

Another #ESMO24 shocker ? IMbrave050 failed to maintain its RFS Benifit declared before . Os immature. Benifit vs Risk ration does not support Atezolizumab plus Bev ax adjuvant therapy for all high risk HCC. So initial positive results have turned negative? Yakup Ergün

Esmo LBAs . One more negative trial. Adjuvant Durvalumab failed to show PFS benifit in completely resected NSCLC. LARVOL Alfredo Addeo MD Patrick Forde Oncology Brothers OncoAlert Brad Loncar Cancer Data etc @esmo #ESMO24

PANDAS-PRODIGE 44 mFOLFIRINOX +/- chemoRT (50.4 Gy) in borderline resectable pancreas cancer. No dif in R0 resection (1 endpt) or OS for all comers…but pCR for chemoRT group was 29% (vs. 8%) & OS improved w chemoRT for pts undergoing resection (48 vs. 36 months). #ESMO24

Presented at #ESMO24: Among patients with limited-stage small-cell lung cancer, overall and progression-free survival were significantly longer with durvalumab adjuvant therapy added to standard concurrent chemoradiotherapy. Full ADRIATIC trial results: nej.md/4d0eZ5m

📣 COG study of 4 large rhabdomyosarcoma trials demonstrated event-free survival benefit for patients who received WLI vs none. To be presented by #vumc peds #radonc Leo Luo at ASTRO 9/30, 8AM (#SS13). Congrats, Dr. Luo! Looking forward to it!   ascopubs.org/doi/10.1200/JC…

So what's the story for day 2 of Esmo24 ? Keynote A18 shows OS benifit. Pembrolizumab in CTRT for cervix. HR 0.67 ( 0.5 to 0.90 ) 82.6 % vs 74.8 % OS at 36 months . OS Benifit seen across all the stages . This should make it new SOC. 🙂👍@esmo #ESMO2024 LARVOL OncoAlert

TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: nej.md/4gg4gqv #ESMO24

5-y results of JCOG 1008 study comparing weekly vs three-weekly cisplatin as concomitant chemoRT for postop head neck cancer. At 5y, weekly non inferior for ✅OS ✅PFS ✅locoregional control Similar toxicity Dr Tahara at #ESMO2024

Congrats to my friend Yungan TAO & GORTEC for this huge trial of IO in LA HNSCC Avelumab-cetuximab inferior to cisplatin CRT in fit patients but superior to cetuximab-RT for PFS in cisplatin ineligible population. #ESMO2024

Hypofractionated #radiation therapy in early #breastcancer - 5-year results from UNICANCER HypoG-01 phase 3 trial #ESMO24 Non inferior as compared to 2Gy-fractionation: moderate hypofractionation preferred standard of care for nodal irradiation OncoAlert #OncoAlert #radonc

#ESMO24 Lung mini-orals🔥 Randomised ph II trial of inhaled corticosteroids in stage III NSCLC treated with cCRT, to reduce radiation pneumonitis: - 292pts - 15% reduction in RP - no long-term steroid tox No need for ph III, could do tomorrow #ESMOAmbassadors #ESMO24 ESMO - Eur. Oncology

Thomas Kennedy leads 10y prostate #SBRT outcomes from 3 different prospective studies now epub at #RedJ IJROBP - The Red Journal doi.org/10.1016/j.ijro… Great biochemical control to 15 years and only 1% chance of mets! Note 10% of UIR pts received ADT and none had whole pelvic RT (-> #PR24)